We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction, and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
CEO Of qordata Chairs Panel On Creating Business Opportunities Using Open Payments Data
Philadelphia, 16th June 2017: Mohammad Ovais, CEO and founder of qordata, chaired an innovation panel at the 8th Aggregate Spend and Sunshine Act Conference.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
Pharma Compliance professionals—like everyone else managing copious amounts of data—will be directly affected by the enforcement of GDPR (General Data Protection Regulation) in May 2018. In this blog, we describe the most important reason for compliance programs to start internalizing process changes introduced by GDPR. GDPR: Why It’s Critical For Transparency/Compliance Professionals As our clients and friends in the pharma industry will confirm, reputational risk—and its preceding penalties–are a compliance professional’s worst nightmare. In previous posts, qordata has described how fines, CMPs (Civil Monetary Penalties) and CIAs (Corporate Integrity Agreements) strike directly at short term sales, and take a longer hit at brand value and equity, goodwill and customer loyalty. Big, Bad Pharma—Now The Cost Is Higher Europe is no […]
In the first week of May, qordata invited Dr. Klaus Geltsetzer to speak on how to “Determine the Relationships of Different Global Disclosure Requirements.” He gave a comprehensive description of compliance efforts across the world, in which transparency and disclosure efforts in Germany yielded some surprising insights. Germany: Bad Boy Or Poster Child Of The Transparency Movement? As Dr. Geltsetzer stated in the webinar, the physician consent rate in Germany hovers close to 30%. In other words, only 1 in 3 physicians agrees to having his/her ToV data published. This means that of the 71,000 HCPs registered in Deutschland, the majority choose not to disclose their individual ToVs (Transfer of Value). What does that mean for transparency? In the €575m […]
In our previous post on Dr. Klaus Geltsetzer’s webinar presentation, how to “Determine the Relationships of Different Global Disclosure Requirements” we described how Germany’s consent rates tell an interesting story, depending on how they’re calculated. We’re resuming the debate on Germany’s position in the pharmaceutical transparency space. This time, we discuss industry-led, private sector synergy. Or lack thereof. As we learnt, thanks to Dr. Klaus Geltsetzer, there are ‘several’ Pharma associations in Europe. Prominent amongst these are: vfa (ca. 150 members) BPI (ca. 240 members) BAH (> 450 members) Pro generica (16 members) That’s an impressive number for one country. It also shows a determined, national effort towards improving pharmaceutical disclosure. Or does it? As Dr. Geltsetzer mentioned, there are over 300 […]